1.
Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications.
2.
3.
4.
Off-label use of orphan medicinal products: a Belgian qualitative study
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
5.
6.
7.
8.
9.
Time Investment in Drug Supply Problems by Flemish Community Pharmacies
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
Table1_Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.DOCX
Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
datasheet1_Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.docx
Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study.